{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Cervical Epidural Analgesia in Head and Neck Cancer Surgery"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "30 patients aged 18-65 years with ASA status I or II scheduled for elective head and neck cancer surgery were randomised into two groups"
      },
      "Participants": {
        "score": 2,
        "evidence": "30 patients aged 18-65 years with ASA status I or II scheduled for elective head and neck cancer surgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Group E (cervical epidural analgesia with general anesthesia) and Group G (general anesthesia alone)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial aimed to assess the impact of cervical epidural analgesia on opioid and anesthetic requirements and stress response in patients undergoing head and neck cancer surgery."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was intra-operative morphine, isoflurane, and vecuronium requirements."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was achieved using a computer-generated sequence, with allocation concealment via sequentially numbered opaque envelopes."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Due to the intervention's nature, blinding was not feasible."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "30 patients aged 18-65 years with ASA status I or II scheduled for elective head and neck cancer surgery were randomised into two groups"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of the 30 patients, 15 were randomised to each group, with 14 in Group E and 15 in Group G completing the study."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Group E demonstrated a significant reduction in morphine (p < 0.001), isoflurane (p = 0.004), and vecuronium (p = 0.001) requirements."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events in Group E included bradycardia in 6.6% and hypotension in 13.3% of patients, both manageable with standard interventions."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not provided."
      },
      "Funding": {
        "score": 1,
        "evidence": "The study reported no financial support."
      }
    },
    "total_score": 16,
    "max_score": 25
  },
  "model": "gpt-4o"
}